Terra Biological Pivots To Pre-IND Trials After FDA Spoils Medical Food Labeling
This article was originally published in The Rose Sheet
FDA warning letter "was a complete surprise to us, especially as we had been advising FDA of our marketing of the CRONaxal product, in writing, for approximately three years as part of our 'orphan drug designation' for glial tumors requirement," says Terra Biological CEO Alan Cook. The firm received an orphan drug designation for oxaloacetate as a treatment for gliomas in 2012.
You may also be interested in...
FDA’s justification report published with Biden administration’s FY2022 federal budget request includes $1.194bn for agency’s food programs, which include its oversight of supplement industry, up from $1.11bn in FY2021 appropriation.
Nestle Health Science acquires IM HealthScience, marketer of medical foods IBgard and FDgard as well as prebiotic and sleep aid supplements. The deal is second recent US consumer health addition for the firm after it said 2020 would be “‘more vigorous” year for acquisitions despite the COVID-19 pandemic.
The trade group and food and drug attorney Scott Bass note FDA's interpretation of medical food stated in its guidance could undermine congressional intent for the category and limit the range of products firms can market as medical foods.